Alaunos Therapeutics' TCR-T Cell Therapy Shows Long-Term Promise in Cancer Treatment

Alaunos Therapeutics has announced an update on its clinical study investigating the long-term safety and efficacy of autologous T cells engineered to express TCRs targeting cancer-specific mutations in solid tumors. The study, which began on March 1, 2023 and is marked as completed, aims to monitor the long-term impact of the Neoantigen specific TCR-T cell drug product on cancer treatment. Successful outcomes could enhance confidence in the company's innovative cancer therapies and position it competitively within the biotech industry.

Alaunos Therapeutics Inc. (TCRT) has announced a significant update on its ongoing clinical study investigating the long-term safety and efficacy of autologous T cells engineered to express T Cell Receptors (TCRs) targeting cancer-specific mutations in solid tumors. The study, titled 'Long-Term Follow-Up Study for Subjects Enrolled in the Phase I/II Study of Autologous T Cells Using the Sleeping Beauty System to Express T Cell Receptors (TCRs) Reactive Against Cancer-specific Mutations in Subjects With Solid Tumors,' aims to monitor the long-term impact of the Neoantigen specific TCR-T cell drug product on cancer treatment.

The study, which began on March 1, 2023, and is now marked as completed, follows a case-only model with a prospective time perspective. It focuses on tracking patients who have previously received the TCR-T cell drug product, focusing on long-term safety and efficacy without administering new study drugs. The last update was submitted on July 28, 2025, indicating the study’s progression and the timeline for data collection and analysis.

The intervention under investigation is the Neoantigen specific TCR-T cell drug product. This biological treatment involves engineered T cells designed to target and react against specific cancer mutations, aiming to provide a personalized therapeutic approach for cancer patients.

The update from Alaunos Therapeutics could influence the company’s stock performance and investor sentiment, as successful outcomes may enhance confidence in the company’s innovative cancer therapies. This development also positions Alaunos competitively within the biotech industry, where advancements in cancer treatment are highly valued.

Further details of the study are available on the ClinicalTrials portal.

References:
[1] https://www.tipranks.com/news/company-announcements/alaunos-therapeutics-tcr-t-cell-study-long-term-impact-on-cancer-treatment
[2] https://pmc.ncbi.nlm.nih.gov/articles/PMC12302805/